Clinical Trial Update: Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy, safety and pharmacokinetics of Octagam 10% in primary immunodeficiency diseases was terminated; results were posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• Octagam 10% (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: Octapharma | Conditions: Immunologic Deficiency Syndromes | Phase 3 | Status: TERMINATED | Results posted: 2017-07-14